Short-term efficacy and safety of new biological agents targeting the interleukin-23–T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis

British Journal of Dermatology

Volumn 176, Issue 3, 2017, Pages 594-603

  Gomez Garcia F ^a,b   Epstein, D ^c   Isla Tejera, B ^a,b   Lorente, A ^a,b   Velez Garcia Nieto A ^a,b   Ruano, J ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 23; PLACEBO; SECUKINUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; BIOLOGICAL FACTOR; DERMATOLOGICAL AGENT;

BIOLOGICAL THERAPY; COCHRANE LIBRARY; DATA EXTRACTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; NETWORK META-ANALYSIS; ODDS RATIO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOM SAMPLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TH17 CELL; TREATMENT DURATION; ADULT; CHRONIC DISEASE; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATIENT SAFETY; PSORIASIS; TREATMENT OUTCOME;

ADULT; BIOLOGICAL FACTORS; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INTERLEUKIN-23; MALE; MIDDLE AGED; PATIENT SAFETY; PSORIASIS; TH17 CELLS; TREATMENT OUTCOME;

EID: 84995493600     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14814     Document Type: Review

References (46)

1. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32:227–55.
2. Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012; 167(Suppl. 3):3–11.
3. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl. 2):1–70.
4. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129:1339–50.
5. Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011; 71:1733–53.
6. Levin AA, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol 2014; 70:555–61.
7. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013; 22:993–1005.
8. Bafeta A, Trinquart L, Seror R, Ravaud P. Reporting of results from network meta-analyses: methodological systematic review. BMJ 2014; 348:g1741.
9. Woolacott N, Hawkins N, Mason A et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10:1–233.
10. Bansback N, Sizto S, Sun H et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009; 219:209–18.
11. Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a Bayesian network meta-analysis. Arch Dermatol 2012; 148:1403–10.
12. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166:179–88.
13. Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis – a systematic review and meta-analysis. J Invest Dermatol 2015; 135:2641–8.
14. Signorovitch JE, Betts KA, Yan YS et al. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol 2015; 172:504–12.
15. Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162:777–84.
16. The Cochrane Collaboration. Assessing risk of bias in included studies. Available at: http://methods.cochrane.org/bias/assessing-risk-bias-included-studies (last accessed 25 August 2016).
17. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64:163–71.
18. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842–7.
19. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51:534–42.
20. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367–74.
21. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56(31):e1–15.
22. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139:1627–32.
23. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014–22.
24. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304–12.
25. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367:29–35.
26. van de Kerkhof PC, Segaert S, Lahfa M et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159:1177–85.
27. Strober BE, Crowley JJ, Yamauchi PS et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165:661–8.
28. Gottlieb AB, Leonardi C, Kerdel F et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165:652–60.
29. Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
30. Bachelez H, van de Kerkhof PC, Strohal R et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015; 386:552–61.
31. Gordon KB, Langley RG, Gottlieb AB et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132:304–14.
32. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106–15.
33. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558–66.
34. Gordon KB, Duffin KC, Bissonnette R et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 2015; 373:136–44.
35. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74.
36. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675–84.
37. Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118–28.
38. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
39. Blauvelt A, Prinz JC, Gottlieb AB et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172:484–93.
40. Paul C, Lacour JP, Tedremets L et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatology Venereol 2015; 29:1082–90.
41. Thaçi D, Blauvelt A, Reich K et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73:400–9.
42. Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
43. Estellat C, Ravaud P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med 2012; 172:237–44.
44. Sofen H, Smith S, Matheson RT et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133:1032–40.
45. Papp K, Thaçi D, Reich K et al. Tildrakizumab (MK-3222), an anti-IL-23p19 monoclonal antibody, improves psoriasis in a phase 2b randomized placebo-controlled trial. Br J Dermatol 2015; 173:930–9.
46. Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin- 17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181–9.